Cambridge Healthtech Institute’s 4th Annual
Cell Therapy Manufacturing, Operations and Logistics
Commercializing Cell Therapies
Part of CHI's Ninth Annual The Bioprocessing Summit

August 23-24, 2017 | Westin Copley Place | Boston, MA

CHI’s Cell Therapy Manufacturing, Operations and Logistics meeting takes an in-depth look at the practicalities of manufacturing autologous and allogenic cell therapies, focusing on key areas such as process development, scalability, bioreactors, next-generation production technologies, automation, closed systems, needle-to-needle logistics, supply chain and facility design. The meeting will feature extensive sessions on CAR-T and TCR production.

Preliminary Agenda

Scale-Up and Commercialization Strategies

Commercialization Challenges in a Cell and Gene Therapy World

Devyn Smith, Ph.D., Head, Operations and Strategy, Medicinal Sciences, Pfizer R&D

Commercial Assessments Beyond COGS: Are Allogeneic Therapies a Better Business Model?

Knut Niss, Ph.D., Asset Leader Cell Therapies and Director, PO&T, Biogen

Next-Generation Cell Therapies

Robert Deans, Ph.D., CTO, Bluerock Therapeutics

Best Practice for a Viable Academic Cell and Gene Therapy Program

Chy-Anh Tran, Ph.D., Associate Director, Operations, Stanford Laboratory for Cell and Gene Medicine, Stanford School of Medicine

Automation, Closed Systems

Approach to Late-Stage Process Development and Characterization of an Allogeneic Cell Therapy Product

Ravinder Bhatia, Ph.D., Director, Pharmaceutical Development and Manufacturing Sciences, Johnson & Johnson

Benefits and Challenges Associated with Automation for Autologous Cellular Therapies - Why One Size Does Not Fit All

Jeff Cram, Ph.D., Senior Scientist, Cellular Process Development and Manufacturing, bluebird bio

GMP Requirements, Process Validation and Lifecycle Management

Talk Title to be Announced

Ohad Karneli, Ph.D., CEO and Co-Founder ATVIO Biotech; Chairman, The Process and Product Committee of the International Society of Cell Therapy (ISCT)

GMP Considerations for Cell-Based Therapies

Trevor Deeks, Ph.D., Consultant, Deeks Pharmaceutical Consulting Services LLC

CAR-T Manufacturing and Characterization Strategies

Challenges and Solutions for Academic to Industry Translation of Personalized Engineered T Cell Therapies

Bruce Levine, Ph.D., Barbara and Edward Netter Professor, Cancer Gene Therapy, Perelman School of Medicine, University of Pennsylvania

Product Characterization Options for CAR-T and TCR Therapies

Sadik H. Kassim, Ph.D., Vice President, Head of Cell Therapy Process and Analytical Development, Mustang Bio

Capacity Management Paradigms in CAR T Cell Therapy Manufacturing

Jon C. Gunther, Ph.D., Senior Engineer, Technical R&D, Juno Therapeutics

Leveraging TALEN, Gene Edited CAR-T Platform to Industrialize Off-The-Shelf Allogeneic Cell-Based Pharmaceuticals

David Sourdive, Ph.D., Executive Vice President, Technical Operations, Cellectis

Manufacturing CAR-T Therapies

Sylvain Arnould, Ph.D., Director, Manufacturing and Production, Celyad

For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Phone: 781-247-6266

For media partnership opportunities, please contact:
Kaushik Chaudhuri
Director of Product Marketing
Phone: 781-972-5419

For exhibit & sponsorship opportunities, please contact:

Companies A-K
Sherry Johnson
Business Development Manager
Phone: 781-972-1359

Companies L-Z
Carolyn Benton
Business Development Manager
Phone: 781-972-5412

OutlookYouTubeFacebookLinkedInTwitter #BPSMT

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Event at a Glance
Event at a Glance

Celebrating 25 Years


Premier Sponsor

Unchained Labs(1)